OmniAb (OABI) Stock: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$4.07
0.12 (3.04%)
▲
5d:
-14.32%
30d:
+19.01%
90d:
+73.93%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: OABI is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: OABI is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $4.07, which is considered fair relative to its 30-day fair value range of $2.98 to $4.70.
Technical Outlook: Technically, OABI is in a strong uptrend. Immediate support is located at $3.89, while resistance sits at $5.43. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: OABI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.40 (+106.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OABI is in a strong uptrend. Immediate support is located at $3.89, while resistance sits at $5.43. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: OABI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.40 (+106.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.98 -
$4.70
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 106.4% below Wall St target ($8.40)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.98 -
$4.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.89
Resistance Level
$5.43
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.80
Wall Street Target
$8.40
(+106.4%)
Revenue Growth (YoY)
244.2%
Profit Margin
-115.1%
Share & Embed Analysis
Last updated: September 13, 2026 7:19 PM ET
Data refreshes hourly during market hours. Next update: 8:19 PM
Data refreshes hourly during market hours. Next update: 8:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
